Pathogenesis of Bartter's syndrome.
D000307:Adrenal Gland Diseases / Q000209:etiology*; D000324:Adrenocorticotropic Hormone / Q000494:pharmacology*; D000418:Albumins / Q000008:administration & dosage*; D000450:Aldosterone / Q000378:metabolism* / Q000652:urine*; D000471:Alkalosis / Q000209:etiology*; D000804:Angiotensin II / Q000494:pharmacology*; D000814:Aniline Compounds / Q000494:pharmacology*; D000927:Anticonvulsants / Q000494:pharmacology*; D002648:Child; D003907:Dexamethasone / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D006929:Hyperaldosteronism / Q000209:etiology*; D006965:Hyperplasia; D006984:Hypertrophy; D007008:Hypokalemia / Q000209:etiology*; D007606:Juxtaglomerular Apparatus; D007668:Kidney / Q000378:metabolism* / Q000473:pathology*; D009638:Norepinephrine / Q000494:pharmacology*; D011188:Potassium / Q000097:blood* / Q000652:urine*; D011189:Potassium Chloride / Q000008:administration & dosage*; D011728:Pyridones / Q000494:pharmacology*; D012083:Renin / Q000097:blood*; D012636:Secretory Rate; D012964:Sodium / Q000378:metabolism*; D013148:Spironolactone / Q000008:administration & dosage*
D000418:Albumins; D000814:Aniline Compounds; D000927:Anticonvulsants; D011728:Pyridones; D000804:Angiotensin II; D013148:Spironolactone; D000450:Aldosterone; D011189:Potassium Chloride; D003907:Dexamethasone; D000324:Adrenocorticotropic Hormone; D012964:Sodium; D012083:Renin; D011188:Potassium; D009638:Norepinephrine